{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T01:10:36Z","timestamp":1762909836940,"version":"3.45.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T00:00:00Z","timestamp":1645660800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005646","name":"Actelion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005646","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine and Research"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.resmer.2022.100893","type":"journal-article","created":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T08:43:36Z","timestamp":1651653816000},"page":"100893","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Risk assessment tools for survival prognosis: An era of new surrogacy endpoints for clinical outcome measurement in pulmonary arterial hypertension clinical trials?"],"prefix":"10.1016","volume":"81","author":[{"given":"Lilian","family":"Sanna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreea","family":"Todea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.resmer.2022.100893_bib0001","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01913-2018","article-title":"Haemodynamic definitions and updated clinical classification of pulmonary hypertension","volume":"53","author":"Simonneau","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resmer.2022.100893_bib0002","first-page":"363","article-title":"World Health Organization Group I pulmonary hypertension: epidemiology and pathophysiology","volume":"34","author":"Prins","year":"2016","journal-title":"Cardiol Clin"},{"key":"10.1016\/j.resmer.2022.100893_bib0003","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1164\/rccm.200510-1668OC","article-title":"Pulmonary arterial hypertension in France: results from a national registry","volume":"173","author":"Humbert","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resmer.2022.100893_bib0004","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1183\/09031936.00042107","article-title":"A USA-based registry for pulmonary arterial hypertension: 1982-2006","volume":"30","author":"Thenappan","year":"2007","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resmer.2022.100893_bib0005","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1378\/chest.09-1140","article-title":"Pulmonary arterial hypertension: baseline characteristics from the REVEAL registry","volume":"137","author":"Badesch","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.resmer.2022.100893_bib0006","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01908-2018","article-title":"Clinical trial design and new therapies for pulmonary arterial hypertension","volume":"53","author":"Sitbon","year":"2019","journal-title":"Eur J Respir"},{"key":"10.1016\/j.resmer.2022.100893_bib0007","first-page":"S97","article-title":"End points and clinical trial design in pulmonary","volume":"54","author":"McLaughlin","year":"2009","journal-title":"Arterial Hypertension"},{"key":"10.1016\/j.resmer.2022.100893_bib0008","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1213917","article-title":"Macitentan and morbidity and mortality in pulmonary arterial hypertension","volume":"369","author":"Pulido","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resmer.2022.100893_bib0009","first-page":"2522","article-title":"Selexipag for the treatment of pulmonary arterial","volume":"373","author":"Sitbon","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.resmer.2022.100893_bib0010","first-page":"834","article-title":"Initial use of ambrisentan plus tadalafil in pulmonary","volume":"373","author":"Gali\u00e8","year":"2015","journal-title":"Arterial Hypertension"},{"key":"10.1016\/j.resmer.2022.100893_bib0011","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1164\/rccm.201908-1640OC","article-title":"Combination therapy with oral treprostinil for pulmonary arterial hypertension. A double-blind placebo-controlled clinical trial","volume":"201","author":"White","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resmer.2022.100893_bib0012","first-page":"92","article-title":"A review of clinical trial endpoints of patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension and how they relate to patient outcomes in the United States","volume":"23","author":"Divers","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.resmer.2022.100893_bib0013","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1161\/CIRCULATIONAHA.112.105890","article-title":"Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials","volume":"126","author":"Gabler","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.resmer.2022.100893_bib0014","unstructured":"Committee for Medicinal Products for Human use (CHMP). Guideline on the clinical investigations of medicinal products for the treatment of pulmonary arterial hypertension, https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-investigations-medicinal-products-treatment-pulmonary-arterial-hypertension_en.pdf. [accessed June 2021 ]."},{"key":"10.1016\/j.resmer.2022.100893_bib0015","unstructured":"Food and Drug Administration. Center for drug evaluation and research. Clinical Outcome Assessment (COA) compendium, https:\/\/www.fda.gov\/media\/130138\/download; 2019 [accessed June 2021 ]."},{"key":"10.1016\/j.resmer.2022.100893_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2019.100486","article-title":"Choosing primary endpoints for clinical trials of health care interventions","volume":"16","author":"McLeod","year":"2019","journal-title":"Contemp Clin Trials Commun"},{"key":"10.1016\/j.resmer.2022.100893_bib0017","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1183\/13993003.01032-2015","volume":"46","author":"Gali\u00e8","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resmer.2022.100893_bib0018","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1002\/sim.5403","article-title":"Biomarkers and surrogate endpoints in clinical trials","volume":"31","author":"Fleming","year":"2012","journal-title":"Stat Med"},{"key":"10.1016\/j.resmer.2022.100893_bib0019","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.jval.2016.10.011","article-title":"Time to review the role of surrogate end points in health policy: state of the art and the way forward","volume":"20","author":"Ciani","year":"2017","journal-title":"Value Health"},{"key":"10.1016\/j.resmer.2022.100893_bib0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002873","article-title":"The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: a cross-sectional study of products authorised 2011-2018","volume":"16","author":"Schuster Bruce","year":"2019","journal-title":"PLoS Med"},{"key":"10.1016\/j.resmer.2022.100893_bib0021","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/1468-0009.12261","article-title":"Timing and characteristics of cumulative evidence available on novel therapeutic agents receiving food and drug administration accelerated approval","volume":"95","author":"Naci","year":"2017","journal-title":"Milbank Q"},{"key":"10.1016\/j.resmer.2022.100893_bib0022","unstructured":"Institute for Clinical and Economic Review (ICER). Strengthening the accelerated approval pathway: an analysis of potential policy reforms and their impact on uncertainty, access, innovation and costs. Available at: https:\/\/icer.org\/wp-content\/uploads\/2021\/04\/Strengthening-the-Accelerated-Approval-Pathway-_-ICER- White-Paper-_-April-2021.pdf. [Last accessed: September 2021 ]"},{"key":"10.1016\/j.resmer.2022.100893_bib0023","unstructured":"Food and Drug Administration. Table of surrogate endpoints that were the basis of drug approval or licensure, https:\/\/www.fda.gov\/drugs\/development-resources\/table-surrogate-endpoints-were-basis-drug-approval-or-licensure; 2021 [accessed June 2021]."},{"key":"10.1016\/j.resmer.2022.100893_bib0024","series-title":"Academia, industry, and regulators, held at the European medicines agency on Monday, June 12, 2017","article-title":"New strategies for the conduct of clinical trials in pediatric pulmonary arterial hypertension: outcome of a multistakeholder meeting with patients","volume":"8","author":"Ollivier","year":"2019"},{"key":"10.1016\/j.resmer.2022.100893_bib0025","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1093\/eurheartj\/ehp297","volume":"30","author":"Gali\u00e8","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.resmer.2022.100893_bib0026","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1016\/j.ehj.2004.09.014","article-title":"Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The task force on diagnosis and treatment of pulmonary arterial hypertension of the European Society of Cardiology","volume":"25","author":"Gali\u00e8","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.resmer.2022.100893_bib0027","doi-asserted-by":"crossref","first-page":"343","DOI":"10.7326\/0003-4819-115-5-343","article-title":"Survival in patients with primary pulmonary hypertension. Results from a national prospective registry","volume":"115","author":"D'Alonzo","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.resmer.2022.100893_bib0028","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1161\/CIRCULATIONAHA.109.911818","article-title":"Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era","volume":"122","author":"Humbert","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.resmer.2022.100893_bib0029","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1183\/09031936.00057010","article-title":"Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension","volume":"36","author":"Humbert","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resmer.2022.100893_bib0030","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1183\/09031936.00004414","article-title":"Validation of two predictive models for survival in pulmonary arterial hypertension","volume":"46","author":"Sitbon","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resmer.2022.100893_bib0031","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1183\/09031936.00072709","article-title":"Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation","volume":"35","author":"Thenappan","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resmer.2022.100893_bib0032","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1378\/chest.11-0969","article-title":"Validation of the pulmonary hypertension connection equation for survival prediction in pulmonary arterial hypertension","volume":"141","author":"Thenappan","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.resmer.2022.100893_bib0033","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1161\/CIRCULATIONAHA.109.898122","article-title":"Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL)","volume":"122","author":"Benza","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.resmer.2022.100893_bib0034","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1093\/eurheartj\/ehx257","article-title":"A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension","volume":"39","author":"Kylhammar","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.resmer.2022.100893_bib0035","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00740-2017","article-title":"Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model","volume":"50","author":"Hoeper","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resmer.2022.100893_bib0036","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00889-2017","article-title":"Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension","volume":"50","author":"Boucly","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resmer.2022.100893_bib0037","doi-asserted-by":"crossref","DOI":"10.1177\/2045894020961739","article-title":"Advanced risk stratification of intermediate risk group in pulmonary arterial hypertension","volume":"10","author":"Yogeswaran","year":"2020","journal-title":"Pulm Circ"},{"key":"10.1016\/j.resmer.2022.100893_bib0038","article-title":"Risk assessment in pulmonary arterial hypertension","volume":"51","author":"Hoeper","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resmer.2022.100893_bib0039","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s12890-018-0712-7","article-title":"A modified risk score in one-year survival rate assessment of group 1 pulmonary arterial hypertension","volume":"18","author":"Xiong","year":"2018","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.resmer.2022.100893_bib0040","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12931-021-01624-z","article-title":"Risk assessment in precapillary pulmonary hypertension: a comparative analysis","volume":"22","author":"Sonnweber","year":"2021","journal-title":"Respir Res"},{"key":"10.1016\/j.resmer.2022.100893_bib0041","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1378\/chest.11-0676","article-title":"The REVEAL registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension","volume":"141","author":"Benza","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.resmer.2022.100893_bib0042","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.chest.2019.02.004","article-title":"Predicting survival in patients with pulmonary arterial hypertension: the REVEAL risk score calculator 2.0 and comparison with ESC\/ERS-based risk assessment strategies","volume":"156","author":"Benza","year":"2019","journal-title":"Chest"},{"key":"10.1016\/j.resmer.2022.100893_bib0043","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1183\/09031936.00196611","article-title":"Predicting survival in pulmonary arterial hypertension in the UK","volume":"40","author":"Lee","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resmer.2022.100893_bib0044","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.chest.2020.08.2069","article-title":"Development and validation of an abridged version of the REVEAL 2.0 risk score calculator, REVEAL Lite 2, for use in patients with pulmonary arterial hypertension","volume":"159","author":"Benza","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.resmer.2022.100893_bib0045","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00008-2020","article-title":"Risk stratification in pulmonary arterial hypertension using Bayesian analysis","volume":"56","author":"Kanwar","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resmer.2022.100893_bib0046","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02004-2018","article-title":"Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension","volume":"53","author":"Humbert","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resmer.2022.100893_bib0047","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.healun.2019.12.013","article-title":"Risk assessment in pulmonary arterial hypertension: insights from the GRIPHON study","volume":"39","author":"Sitbon","year":"2020","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.resmer.2022.100893_bib0048","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00673-2020","article-title":"Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension","volume":"56","author":"Sitbon","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resmer.2022.100893_bib0049","first-page":"199","article-title":"Risk scores and risk-based stratification of clinical worsening events in pulmonary arterial hypertension participants treated with oral treprostinil: freedom-EV","author":"White","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resmer.2022.100893_bib0050","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11906-019-0950-y","article-title":"The use of risk assessment tools and prognostic scores in managing patients with pulmonary arterial hypertension","volume":"21","author":"Kanwar","year":"2019","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.resmer.2022.100893_bib0051","doi-asserted-by":"crossref","first-page":"4182","DOI":"10.1093\/eurheartj\/ehx301","article-title":"Validation of a risk assessment instrument for pulmonary arterial hypertension","volume":"39","author":"Weatherald","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.resmer.2022.100893_bib0052","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0141911","article-title":"Pulmonary hypertension in patients with chronic fibrosing idiopathic interstitial pneumonias","volume":"10","author":"Hoeper","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.resmer.2022.100893_bib0053","doi-asserted-by":"crossref","unstructured":"Humbert M., Sitbon O., Chaouat A., Bertocchi M., Habib G., Gressin V., et\u00a0al. Pulmonary arterial hypertension in France. Am J Respir Crit Care Med 2006;173:1023\u201330.","DOI":"10.1164\/rccm.200510-1668OC"},{"key":"10.1016\/j.resmer.2022.100893_bib0054","doi-asserted-by":"crossref","unstructured":"McGoon M.D., Miller D.P. REVEAL: a contemporary US pulmonary arterial hypertension registry. Eur Respir Rev 2012;21:8\u201318.","DOI":"10.1183\/09059180.00008211"},{"key":"10.1016\/j.resmer.2022.100893_bib0055","unstructured":"Clinicaltrials.gov. REVEAL Registry\u2122: registry to evaluate early and long-term PAH disease management. Available at: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00370214. [Last accessed: September 2021 ]"},{"key":"10.1016\/j.resmer.2022.100893_bib0056","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1209655","article-title":"Riociguat for the treatment of pulmonary arterial hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N Engl J Med"}],"container-title":["Respiratory Medicine and Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590041222000101?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590041222000101?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T01:06:17Z","timestamp":1762909577000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590041222000101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":56,"alternative-id":["S2590041222000101"],"URL":"https:\/\/doi.org\/10.1016\/j.resmer.2022.100893","relation":{},"ISSN":["2590-0412"],"issn-type":[{"type":"print","value":"2590-0412"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk assessment tools for survival prognosis: An era of new surrogacy endpoints for clinical outcome measurement in pulmonary arterial hypertension clinical trials?","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine and Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resmer.2022.100893","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"100893"}}